Subsequently, the ASCO Technology Assessment recommended that optimal adjuvant hormonal therapy for a postmenopausal woman with HR+ early breast cancer should now include an aromatase inhibitor either as initial therapy or after treatment with tamoxifen (Winer et al, 2005). This evidence concerns the gene CYP19A1 and breast cancer.